TB
Thylacine Bio develops a peptide platform for creating broad-spectrum antiviral therapeutics targeting persistent and emerging respiratory viruses. Their approach focuses on conserved viral regions to ensure efficacy across variants, resulting in potent, self-administered treatments. The platform is designed for rapid tuning to address new and existing pathogens for disease treatment, infection prevention, and transmission blocking.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Thylacine Bio develops a peptide platform for creating broad-spectrum antiviral therapeutics targeting persistent and emerging respiratory viruses. Their approach focuses on conserved viral regions to ensure efficacy across variants, resulting in potent, self-administered treatments. The platform is designed for rapid tuning to address new and existing pathogens for disease treatment, infection prevention, and transmission blocking.